139 related articles for article (PubMed ID: 3097099)
1. Coronary thrombolysis with recombinant tissue-type plasminogen activator: patency rate and regional wall motion after 3 months.
Jang IK; Vanhaecke J; De Geest H; Verstraete M; Collen D; Van de Werf F
J Am Coll Cardiol; 1986 Dec; 8(6):1455-60. PubMed ID: 3097099
[TBL] [Abstract][Full Text] [Related]
2. Anistreplase versus alteplase in acute myocardial infarction: comparative effects on left ventricular function, morbidity and 1-day coronary artery patency. The TEAM-3 Investigators.
Anderson JL; Becker LC; Sorensen SG; Karagounis LA; Browne KF; Shah PK; Morris DC; Fintel DJ; Mueller HS; Ross AM
J Am Coll Cardiol; 1992 Oct; 20(4):753-66. PubMed ID: 1527286
[TBL] [Abstract][Full Text] [Related]
3. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. RAPID Investigators.
Smalling RW; Bode C; Kalbfleisch J; Sen S; Limbourg P; Forycki F; Habib G; Feldman R; Hohnloser S; Seals A
Circulation; 1995 Jun; 91(11):2725-32. PubMed ID: 7758177
[TBL] [Abstract][Full Text] [Related]
4. Prevention of coronary artery reocclusion and reduction in late coronary artery stenosis after thrombolytic therapy in patients with acute myocardial infarction. A randomized study of maintenance infusion of recombinant human tissue-type plasminogen activator.
Johns JA; Gold HK; Leinbach RC; Yasuda T; Gimple LW; Werner W; Finkelstein D; Newell J; Ziskind AA; Collen D
Circulation; 1988 Sep; 78(3):546-56. PubMed ID: 3136953
[TBL] [Abstract][Full Text] [Related]
5. Quantitative radionuclide assessment of regional ventricular function after thrombolytic therapy for acute myocardial infarction: results of phase I Thrombolysis in Myocardial Infarction (TIMI) trial.
Wackers FJ; Terrin ML; Kayden DS; Knatterud G; Forman S; Braunwald E; Zaret BL
J Am Coll Cardiol; 1989 Apr; 13(5):998-1005. PubMed ID: 2494246
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of late coronary thrombolysis (recombinant tissue-type plasminogen activator) in preserving left ventricular function in acute myocardial infarction.
Villari B; Piscione F; Bonaduce D; Golino P; Lanzillo T; Condorelli M; Chiariello M
Am J Cardiol; 1990 Dec; 66(19):1281-6. PubMed ID: 2123072
[TBL] [Abstract][Full Text] [Related]
7. Thrombolysis with intravenous human recombinant tissue-type plasminogen activator in acute myocardial infarction: the European experience.
de Bono DP
J Am Coll Cardiol; 1987 Nov; 10(5 Suppl B):75B-78B. PubMed ID: 2959717
[TBL] [Abstract][Full Text] [Related]
8. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI-1) trial: influence of infarct location on arterial patency, left ventricular function and mortality.
Bates ER; Califf RM; Stack RS; Aronson L; George BS; Candela RJ; Kereiakes DJ; Abbottsmith CW; Anderson L; Pitt B
J Am Coll Cardiol; 1989 Jan; 13(1):12-8. PubMed ID: 2521226
[TBL] [Abstract][Full Text] [Related]
9. A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: the PACT trial. PACT investigators. Plasminogen-activator Angioplasty Compatibility Trial.
Ross AM; Coyne KS; Reiner JS; Greenhouse SW; Fink C; Frey A; Moreyra E; Traboulsi M; Racine N; Riba AL; Thompson MA; Rohrbeck S; Lundergan CF
J Am Coll Cardiol; 1999 Dec; 34(7):1954-62. PubMed ID: 10588209
[TBL] [Abstract][Full Text] [Related]
10. Coronary patency, infarct size and left ventricular function after thrombolytic therapy for acute myocardial infarction: results from the tissue plasminogen activator: Toronto (TPAT) placebo-controlled trial. TPAT Study Group.
Morgan CD; Roberts RS; Haq A; Baigrie RS; Daly PA; Gent M; Armstrong PW
J Am Coll Cardiol; 1991 Jun; 17(7):1451-7. PubMed ID: 1903404
[TBL] [Abstract][Full Text] [Related]
11. Thrombolysis and coronary occlusion: effects upon the non-infarct zone.
Cranswick R; Carter G; Wilkes N; Nelson G
Eur Heart J; 1992 Jun; 13(6):770-5. PubMed ID: 1623865
[TBL] [Abstract][Full Text] [Related]
12. HTUPA as a new thrombolytic agent for acute myocardial infarction: a multicenter, randomized study.
Sun Y; Liu X; Guo L; Pang W; Guo X; Sun Z; Li Z; Cui X; Li H; Tao G; Wang L; Zhou C; Liu Y; Shan H; Wang M; Liu M; Li J; Yin L; Hu D
Int J Cardiol; 2014 Mar; 172(2):326-31. PubMed ID: 24525155
[TBL] [Abstract][Full Text] [Related]
13. Effect of time of 7E3 administration on rt-PA-induced reperfusion: study in a canine model of thrombus-based occlusion-reperfusion.
Rebello SS; Huang J; Saito K; Saucedo JF; Bates ER; Lucchesi BR
Eur J Pharmacol; 1999 Jun; 374(3):399-410. PubMed ID: 10422784
[TBL] [Abstract][Full Text] [Related]
14. Sequential combination thrombolytic therapy for acute myocardial infarction: results of the Pro-Urokinase and t-PA Enhancement of Thrombolysis (PATENT) Trial.
Zarich SW; Kowalchuk GJ; Weaver WD; Loscalzo J; Sassower M; Manzo K; Byrnes C; Muller JE; Gurewich V
J Am Coll Cardiol; 1995 Aug; 26(2):374-9. PubMed ID: 7608437
[TBL] [Abstract][Full Text] [Related]
15. Coronary thrombolysis and myocardial salvage by tissue plasminogen activator given up to 4 hours after onset of myocardial infarction. National Heart Foundation of Australia Coronary Thrombolysis Group.
Lancet; 1988 Jan; 1(8579):203-8. PubMed ID: 2893038
[TBL] [Abstract][Full Text] [Related]
16. Effect of intravenous streptokinase as compared with that of tissue plasminogen activator on left ventricular function after first myocardial infarction.
White HD; Rivers JT; Maslowski AH; Ormiston JA; Takayama M; Hart HH; Sharpe DN; Whitlock RM; Norris RM
N Engl J Med; 1989 Mar; 320(13):817-21. PubMed ID: 2494454
[TBL] [Abstract][Full Text] [Related]
17. Acute coronary thrombolysis with recombinant human tissue-type plasminogen activator: initial patency and influence of maintained infusion on reocclusion rate.
Verstraete M; Arnold AE; Brower RW; Collen D; de Bono DP; De Zwaan C; Erbel R; Hillis WS; Lennane RJ; Lubsen J
Am J Cardiol; 1987 Aug; 60(4):231-7. PubMed ID: 3113222
[TBL] [Abstract][Full Text] [Related]
18. A double blind placebo controlled study of early and late administration of recombinant tissue plasminogen activator in acute myocardial infarction.
McNeill AJ; Cunningham SR; Flannery DJ; Dalzell GW; Wilson CM; Campbell NP; Khan MM; Patterson GC; Webb SW; Adgey AA
Br Heart J; 1989 Apr; 61(4):316-21. PubMed ID: 2496740
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of streptokinase, but not tissue-type plasminogen activator, in achieving 90-minute patency after thrombolysis for acute myocardial infarction decreases with time to treatment. PERM Study Group. Prospective Evaluation of Reperfusion Markers.
Steg PG; Laperche T; Golmard JL; Juliard JM; Benamer H; Himbert D; Aubry P
J Am Coll Cardiol; 1998 Mar; 31(4):776-9. PubMed ID: 9525545
[TBL] [Abstract][Full Text] [Related]
20. Coronary arterial thrombolysis with low-dose synergistic combinations of recombinant tissue-type plasminogen activator (rt-PA) and recombinant single-chain urokinase-type plasminogen activator (rscu-PA) for acute myocardial infarction.
Collen D; Van de Werf F
Am J Cardiol; 1987 Sep; 60(7):431-4. PubMed ID: 3115077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
